Mortality Outcome of Controlled Hypertension

NCT07187596 | Active Not Recruiting

• 2 other identifiers: NathaphongDejthidaCRD420251072526
• Study Type: observational
• Target: 2,547
• Locations: 1 country
• Sites: 1

Brief Summary

This review focuses on the assumption of mortality outcome of participants remaining label hypertension care is adequately managed when pressure targets are met with both qualitative and quantitaive method.

Conditions

Arterial Aneurysm; Arterial Rupture; Renal Disease; Artery Stenosis; Maternal Death; Hypertension; Morality; Death; Pre-Eclampsia; Stroke; Cardiovascular Diseases

Keywords

Controlled blood pressure; Mortality outcomes

Outcome Measures

Primary Outcomes (1)

• All-cause vascular mortality

  Cardiovascular mortality (Cardiac-related death in controlled hypertension patients), cerebrovascular death(Stroke-related fatal outcomes in BP-controlled patients), renal occlusion/rupture/failure causing death (Mortality from renal failure in treated, controlled hypertensives), life-threatening vascular rupture, Major Adverse Cardiovascular Death or

  Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 10 years

Secondary Outcomes (5)

• Sudden death

  Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 10 years

• End-organ failure leading to death

  90 days outcomes after participant recruitment (death/alive)

• ICU death

  90 days outcomes start with day 1 admit at ICU (death/alive)

• Maternal associated hypertension death

  During pregnancy period from GA 1 week to delivery (pre-term, term-post-term) to 6 week follow up postpartum

• Hypertension associated death in the young

  Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 18 years of ages of participant

Study Arms (1)

Mortality outcomes

Mortality outcomes or casue which mainly suspected from hypertension

Eligibility Criteria

• Age: 1 Minute - 130 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Studies including patients (any age or sex) with: * Interventional treatment for hypertension * Documented blood pressure control (as defined by each primary study) * Reported mortality or fatal outcome

You may qualify if:

• Human birth in all sex chromosomes.
• Study reports evidence of living with owned systemic/arterial hypertension by one of definition following;
• Quantitative: Blood pressure number higher over the normal range by each protocol in mmHg unit in any arm of study.
• Qualitative: Clarify the underwent both retrospective, observation or intervention of blood pressure and clearly clarify number of hypertension participants in article.
• Study design: any type of studies and have a doi number.
• In case report type study, the article recruit in only high blood pressure is a burden that reports both direct intervention for blood pressure or indirect intervention such as treatment of vascular damage from high blood pressure.
• In a group of literature review type study, the number of hypertension participants with references from both in supplementary document or traced back via each doi number have to clearly declare in that free full-text and currently non-retracted article without personal requirement as raw material to processing the individual participant data meta-analysis
• Study recruit only last version of study series that have to confirm published the hypertension participant with mortality outcomes.
• English-language studies.

You may not qualify if:

• Non human/human-specimen studies.
• Evidence confirms local site or specific system hypertension only such as studies of pulmonary hypertension, portal hypertension, ocular hypertension without clearly defining the number of systemic arterial hypertension in articles.
• No report of conclusion of participant such as no mortality report, no failed/successful outcome from last follow up from hypertension associated life-threatening event.
• Deaths due to suicide, trauma, or illegal drugs including intend to take medication overdose in any reason.
• Book, Testimonial, Interview, Conference, Protocol articles.
• Sub-group analysis.
• Duplicate one of the doi/nct/prospero numbers.
• No doi. Number

Sponsors & Collaborators

• DejthidaNathaphong: lead

Study Sites (1)

Owned study

Bangkok, Bangkok, 10110, Thailand

Location

Related Links

• PROSPERO registry

MeSH Terms

Conditions

Hypertension; Death; Pre-Eclampsia; Cardiovascular Diseases; Stroke; Kidney Diseases; Maternal Death

Condition Hierarchy (Ancestors)

Vascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Urologic Diseases; Female Urogenital Diseases; Male Urogenital Diseases; Parental Death

Study Officials

• Nathaphong Dejthida, MD

  DejthidaNathaphong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: September 9, 2025
• First Posted: September 23, 2025
• Study Start: September 18, 2025
• Primary Completion (Estimated): December 18, 2026
• Study Completion (Estimated): December 14, 2027
• Last Updated: July 29, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
• Time Frame: TIMELINE OF THE REVIEW Date of first submission to PROSPERO 01 July 2025 Review timeline Start date: 14 June 2025. End date: 31 December 2026. Date of registration in PROSPERO 01 July 2025
• Access Criteria: Public registered

Locations

TH (1)